SurGenTec

Executive Summary

SurGenTec is a privately held medical device company focused on minimally invasive spine and orthopedic solutions, with a strong emphasis on regenerative medicine and surgical fixation. Founded in 2015 and headquartered in Boca Raton, Florida, the company has developed a portfolio of innovative products including the TILINK-P® SI Joint Fusion System for sacroiliac joint dysfunction, the ION-C™ Cervical Implant System for cervical disc replacement, and OsteoFlo® HydroFiber™ bone graft substitutes designed to enhance fusion and healing. These products address critical needs in spinal surgery by offering less invasive procedures, improved patient outcomes, and faster recovery times. SurGenTec's technology leverages advanced biomaterials and precise instrumentation to compete in the growing $10+ billion spine surgery market. The company is well-positioned to capture market share as the demand for minimally invasive and biologic-enhanced solutions increases. With a focus on clinical evidence and surgeon education, SurGenTec aims to expand its commercial footprint. Key upcoming drivers include potential FDA clearances for product line extensions, broadening of indications for existing devices, and strategic partnerships to accelerate distribution. While privately held, the company's innovative portfolio and focus on high-growth segments warrant attention. The conviction score reflects a solid product pipeline but limited public financial disclosure.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance for next-generation SI joint fusion implant with improved biologic integration70% success
• Q2 2026Publication of clinical study results for ION-C cervical implant demonstrating superior outcomes60% success
• Q3 2026Strategic partnership or distribution agreement for OsteoFlo bone graft substitutes in international markets75% success